A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study)
Latest Information Update: 02 May 2024
At a glance
- Drugs Iron-sucrose/tin-protoporphyrin (Primary)
- Indications Acute kidney injury
- Focus Biomarker; Therapeutic Use
- Acronyms START
- Sponsors Renibus Therapeutics
- 26 Apr 2024 According to a Renibus Therapeutics media release, data from this study will be presented at the the American Association for Thoracic Surgery (AATS) 104th Annual Meeting and the Society of Cardiovascular Anesthesiologists (SCA) 46th Annual Meeting, both taking place in Toronto, Canada, April 27-30, 2024.
- 09 Jan 2024 According to a Renibus Therapeutics media release, company publication in E-Clinical Medicine, part of The Lancet Discovery Science, of results from this study.
- 09 Jan 2024 Results presented in a Renibus Therapeutics Media Release.